Vasilios Papavasiliou
Montreal, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
The CHI3L1-neutrophil axis drives immune suppression and breast cancer metastatic dissemination.
Journal: JCI insight
Published: August 20, 2025
EZH2 directs HER2+ breast cancer progression through the modulation of epithelial plasticity.
Journal: EMBO reports
Published: July 15, 2025
HER2∆16 directs luminal cell identity and estrogen receptor signaling in HER2+ breast cancer.
Journal: Nature communications
Published: June 03, 2025
Osteopontin is a therapeutic target that drives breast cancer recurrence.
Journal: Nature communications
Published: April 05, 2024
Targeting fatty acid oxidation enhances response to HER2-targeted therapy.
Journal: Nature communications
Published: January 10, 2024
The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer.
Journal: Immunity
Published: March 23, 2023
Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression.
Journal: The Journal of clinical investigation
Published: June 22, 2022
HER2Δ16 Engages ENPP1 to Promote an Immune-Cold Microenvironment in Breast Cancer.
Journal: Cancer immunology research
Published: February 24, 2022
Nanoliposome targeting in breast cancer is influenced by the tumor microenvironment.
Journal: Nanomedicine : nanotechnology, biology, and medicine
Published: October 04, 2018
An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis.
Journal: Nature communications
Published: August 23, 2018
Translational and HIF-1α-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides.
Journal: Cell metabolism
Published: July 06, 2017
Showing 1-11 of 11
Last Updated: 09/26/2026